Cassidy J et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007;Abstract 270.

Grothey A et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). Proc ASCO 2007;Abstract 4036.

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004;350(23):2335-42. Abstract

Maindrault-Goebel F et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. Proc ASCO 2007;Abstract 4013.

Malik Z, Eng C. The use of cetuximab after oxaliplatin-based chemotherapy in a patient with
metastatic colorectal cancer. Clin Adv Hematol Oncol 2007;5(1 Suppl 1):4-7. No abstract available

Marshall JL. Bevacizumab in the treatment of colorectal cancer. Clin Adv Hematol Oncol.
2007;5(1 Suppl 1):8-9. No abstract available

Saltz LB et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007;Abstract 238.

Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR study. J Clin Oncol 2006;24(3):394-400. Abstract

Venook A et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc ASCO 2006;Abstract 3509.